-
Mashup Score: 3ATG versus ATLG as prophylaxis for graft-versus-host disease in alloSCT: a comparative study - 15 hour(s) ago
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, comments on a prospective comparative study of anti-T lymphocyte globulin (ATG) and grafalon (ATLG) as prophylaxis for graft-versus-host disease in allogeneic stem cell transplantation (alloSCT). Dr Gavriilaki notes that the study’s preliminary data suggest a significant difference in survival between patients receiving ATLG versus ATG. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 4Shaping the future of R/R follicular lymphoma treatment: a focus on bispecific antibodies - 21 hour(s) ago
VJHemOnc is pleased to share a feature article that explores the value of bispecific antibodies in the treatment of R/R follicular lymphoma.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
Bispecific antibodies are becoming a game-changer in R/R follicular lymphoma. Check out our recent article, which explores these agents and features expert insights from Lorenzo Falchi (@MSKCancerCenter). Read more below! πhttps://t.co/Hvma9xUg24 #LymSM #HemOnc #ImmunoOnc https://t.co/zdYozJ9MJJ
-
-
Mashup Score: 5The CAR T Vision project: doubling the number of patients receiving CAR T-cell therapy by 2030 - 24 hour(s) ago
Currently, only approximately 20-25% of patients with hematological malignancies who are eligible for CAR T-cell therapy receive this treatment. In this interview, Jason Westin, MD, MS, FACP, FASCO, The University of Texas MD Anderson Cancer Center, Houston, TX, introduces the CAR T Vision projectβa collaborative effort aimed at doubling the number of patients receiving CAR T-cell therapy by 2030. Prof. Westin emphasizes the importance of bringing together relevant stakeholders, including physicians, patient advocates, payers, and hospital organizations, to achieve this ambitious goal. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
What is the CAR T Vision project, and what are its main aims? π©Έπ Watch our interview with Jason Westin (@Lymphoma_Doc) of @MDAndersonNews to find out: π₯ https://t.co/eaYiuh3Ea8 #ASCO25 #CARTCell #ImmunoOnc #HemOnc
-
-
Mashup Score: 2The MPN Workshop of the Carolinas 2025: sharing the latest data and updates in the MPN field - 2 day(s) ago
In this video, Rupali Bhave, MD, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, shares her enthusiasm for the upcoming MPN Workshop of the Carolinas 2025, highlighting it as a unique opportunity to learn from leading experts in the field of myeloproliferative neoplasms (MPNs). This 48-hour workshop will allow participants to hear recent data and advances in essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), as well as less common MPNs and overlap syndromes. Dr Bhave expresses her excitement to attend and learn from the speakers, citing her positive experience from last year’s event. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
From cutting-edge MPN data to clinical updates β we're sure to hear all that and more next week at the 2nd MPN Workshop of the Carolinas!π©Έ π₯ Dr Rupali Bhave shares what to expect & why you wonβt want to miss this event: π https://t.co/L06ME7XxG8 π Register your in-person or
-
-
Mashup Score: 2Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial - 2 day(s) ago
In this episode of the VJHemOnc Podcast, we dive into one of the more aggressive and challenging manifestations of multiple…
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
π New VJHemOnc Podcast! Extramedullary disease (EMD) in #MultipleMyeloma: what is it, how do we treat it, and what's next? Experts unpack the biology, clinical challenges & the RedirecTT-1 trial. π§ Dive in: https://t.co/9QkjMmO0KL #MMsm #HemOnc #ImmunoOnc https://t.co/vfcZdphLkw
-
-
Mashup Score: 2ReVenG trial: safety & efficacy of venetoclax plus obinutuzumab retreatment in patients with R/R CLL - 3 day(s) ago
In this video, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into the ReVenG trial (NCT04895436), which is evaluating the efficacy of venetoclax retreatment in patients with relapsed chronic lymphocytic leukemia (CLL) who previously received this agent in the frontline setting. Dr Davids presents early data from the trial, which shows promising efficacy and a similar safety profile to the frontline setting, with 15 out of 25 patients responding to retreatment and achieving undetectable measurable residual disease (MRD) in many cases. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
It's always fantastic to catch up with @DrMDavids of @DanaFarber!π Recently, at #18ICML, Dr Davids shared insights into the ReVenG trial, evaluating the safety & efficacy of venetoclax plus obinutuzumab retreatment in R/R CLL. Watch now: π https://t.co/zX7GsH8WSv π #CLLsm
-
-
Mashup Score: 2Impact of EBV status on outcomes with nivo-AVD versus BV-AVD in patients with Hodgkin lymphoma - 3 day(s) ago
Sairah Ahmed, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the results of SWOG S1826 (NCT03907488), a clinical trial comparing nivolumab-AVD (nivo-AVD) versus brentuximab vedotin-AVD (BV-AVD) in patients with advanced-stage Hodgkin lymphoma (HL). Dr Ahmed notes that EpsteinβBarr virus (EBV)-positive patients demonstrated better outcomes with nivo-AVD compared to BV-AVD, suggesting that this subset of patients benefits from the incorporation of checkpoint inhibition into their treatment regimen. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
π₯ Sairah Ahmed of @MDAndersonNews comments on the impact of EBV status on outcomes with nivo-AVD versus BV-AVD in patients with Hodgkin #lymphoma: π https://t.co/ttEswaHN86 π #HodgkinLymphoma #LYMsm #18ICML #ImmunoOnc #HemOnc
-
-
Mashup Score: 8Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more - 4 day(s) ago
In this discussion, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, Doris Hansen, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key updates on the use of T-cell engagers in multiple myeloma. The experts share insights into how they use teclistamab and elranatamab in clinical practice, and then discuss the role of the GPRC5D-directed bispecific antibody talquetamab. Following this, they discuss the potential of dual-targeting approaches, highlighting ongoing studies in this space. To conclude, the experts discuss how to best sequence CAR T-cells and bispecifics, and share their perspectives on the most exciting immunotherapy updates to keep an eye out for in the field of myeloma. This discussion took place at the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025 held in Miami, F
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
At #iwCART25 earlier this year, we brought together leading experts @YiLinMDPhD, @DrRakeshPopat, Doris Hansen, & Sham Mailankody to discuss practical considerations for using T-cell engagers in #MultipleMyeloma.π©Έ Watch here: π https://t.co/h8GBGEEFY6 π #MMSM #Myeloma
-
-
Mashup Score: 2Community Focus Archives | VJHemOnc - 4 day(s) ago
Intended for community physicians, this channel aims to inform clinical practice through expert interviews from major international congresses. The diagnosis, treatment and management of patients with hematological conditions and malignancies is rapidly evolving, and with an influx of therapeutic options, physicians may find it difficult to decide which management strategy is best for their patients. Although cutting-edge research is at the heart of clinical development, data from trials are not always
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
Introducing: the Community Focus channel!π©ββοΈπ¨ββοΈ This channel aims to inform clinical practice through expert interviews from international congresses.π₯ π₯ Designed for HCPs to help bridge the gap between research & care. Check it out here: π https://t.co/UMwJjYuHtn #HemOnc https://t.co/PeJH6ro07b
-
-
Mashup Score: 4
Juraj ΔuraΕ‘, MD, Ostrava University Hospital, Ostrava, Czech Republic, shares the findings of a matching-adjusted indirect comparison (MAIC) of epcoritamab plus R-miniCHOP versus R-miniCHOP in elderly patients with diffuse large B-cell lymphoma (DLBCL). He notes that the combination of epcoritamab plus R-miniCHOP resulted in higher complete response rates, progression-free survival, and overall survival compared to R-miniCHOP alone. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
In an interview from #18ICML, Juraj ΔuraΕ‘ shares the findings of a matching-adjusted indirect comparison of epcoritamab plus R-miniCHOP versus R-miniCHOP in elderly patients with #DLBCL. Click here to watch: π https://t.co/3SvZTQJWcx π #LYMsm #Lymphoma #ImmunoOnc #HemOnc
-
We caught up with the lovely @elenicelli of @Auth_University at #EHA2025 to hear about a comparative study of ATG versus ATLG as GvHD prophylaxis in alloSCT.π©Έ Watch the interview here: π₯ https://t.co/kkpyjaN2VD #HemOnc #BMTsm #Hematology